Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Launches US Subsidiary

NEW YORK (GenomeWeb) – Cellectis today announced it has established a new subsidiary in New York to serve as the Paris-based firm's US headquarters. Cellectis, Inc. will feature laboratory space to develop engineered chimeric antigen receptor (CAR) T cells for gene editing-based cancer therapy.

The subsidiary will nestle in at the Alexandria Center for Life Science, a biotechnology development hub on Manhattan's East side near the city's major biomedical research centers, including New York University and Rockefeller University. Other tenants at the development include Eli Lilly, Roche, and Pfizer.

"At the Alexandria Center for Life Science, Cellectis is surrounded by renowned academic and medical institutions, leaders from the commercial life sciences industry, and the world's most robust financial markets," Cellectis Founder and CEO André Choulika said in a statement.

Cellectis is developing cancer immunotherapies based on engineered chimeric antigen receptor T cells. The firm said it has more than 15 years of expertise in genome engineering, based on its transcription activator-like effector nuclease, meganuclease, and pulse agile technology.

In January, Cellectis priced an American initial public offering and began trading on the Nasdaq under ticker symbol "CLLS."